Tumor angiogenesis plays essential roles during
lung cancer progression and
metastasis. Therapeutic agent that targets both
tumor cell and vascular endothelial cell may achieve additional anti-
tumor efficacy. We demonstrate that
bedaquiline, a FDA-approved
antibiotic drug, effectively targets
lung cancer cells and angiogenesis.
Bedaquiline dose-dependently inhibits proliferation and induces apoptosis of a panel of
lung cancer cell lines regardless of subtypes and molecular heterogeneity.
Bedaquiline also inhibits capillary network formation of human lung
tumor associated-endothelial cell (HLT-EC) on
Matrigel and its multiple functions, such as spreading, proliferation and apoptosis, even in the presence of
vascular endothelial growth factor (
VEGF). We further demonstrate that
bedaquiline acts on
lung cancer cells and HLT-EC via inhibiting mitochondrial respiration and glycolysis, leading to
ATP reduction and oxidative stress. Consistently, oxidative damage on
DNA,
protein and
lipid were detected in cells exposed to
bedaquiline. Importantly, the results obtained in in vitro cell culture are reproducible in in vivo xenograft
lung cancer mouse model, confirming that
bedaquiline suppresses lug
tumor growth and angiogenesis, and increases oxidative stress. Our findings demonstrating that energy depletion is effectively against lung
tumor cells and angiogenesis. Our work also provide pre-clinical evidence to repurpose
antibiotic bedaquiline for
lung cancer treatment.